Administration of recombinant activated factor VII (NovoSeven) in three cases of uncontrolled bleeding caused by disseminated intravascular coagulopathy

被引:7
作者
Schmid, Stefan
Friesenecker, Barbara
Lorenz, Ingo
Innerhofer, Petra
Koscielny, Juergen
Velik-Salchner, Corinna
Mutz, Norbert
Fries, Dietmar
机构
[1] Innsbruck Med Univ, Dept Gen & Surg Crit Care Med, A-6020 Innsbruck, Austria
[2] Humboldt Univ, Inst Transfus Med, Berlin, Germany
关键词
rFVIIa; disseminated intravascular coagulopathy; disseminated intravascular coagulation; bleeding;
D O I
10.1177/1076029607302567
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recombinant activated factor VII has been used successfully in many cases of traumatic and surgical bleeding complications that were unresponsive to standard treatment. However, because disseminated intravascular coagulation can develop from a thrombin burst as a side effect of recombinant activated factor VII, it is not yet established for bleeding complications induced by disseminated intravascular coagulation. This article presents 3 patients with severe sepsis and fulminant disseminated intravascular coagulation. Excessive microvascular bleeding persisted despite conventional therapy, and surgical intervention and radiologic embolization did not control bleeding. After administration of recombinant activated factor VII, bleeding ceased in all patients, and no overt thromboembolic events occurred. One patient survived to be discharged from the hospital. The other 2 patients died from refractory multiorgan failure and overall poor prognosis. Recombinant factor Vila might be an option for the treatment of severe bleeding complications in the case of DIC refractory to the conventional therapy.
引用
收藏
页码:313 / 317
页数:5
相关论文
共 19 条
[1]  
Alving BM, 1998, HEMATOLOGY, P320
[2]   Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients [J].
Chowdhury, P ;
Saayman, AG ;
Paulus, U ;
Findlay, GP ;
Collins, PW .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (01) :69-73
[3]  
CID AR, 2003, 19 C INT SOC THROMB
[4]   Coagulopathy of sepsis [J].
Dempfle, CE .
THROMBOSIS AND HAEMOSTASIS, 2004, 91 (02) :213-224
[5]   Bleeding and thrombotic complications in critically ill patients with cancer [J].
DeSancho, MT ;
Rand, JH .
CRITICAL CARE CLINICS, 2001, 17 (03) :599-+
[6]   Disseminated intravascular coagulation in trauma patients [J].
Gando, S .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2001, 27 (06) :585-592
[7]   On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life-threatening haemorrhage: focus on prothrombin activation [J].
Gerotziafas, GT ;
Zervas, K ;
Arzoglou, P ;
Karavaggeli, E ;
Parashou, S ;
Van Dreden, P ;
Christakis, J ;
Samama, MM .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (03) :705-708
[8]   Successful reversal of deleterious coagulopathy by recombinant factor VIIa [J].
Haas, T ;
Innerhofer, P ;
Kühbacher, G ;
Fries, D .
ANESTHESIA AND ANALGESIA, 2005, 100 (01) :54-58
[9]  
Hambleton Julie, 2002, Hematology Am Soc Hematol Educ Program, P335
[10]   Advances in the understanding of the pathogenetic pathways of disseminated intravascular coagulation result in more insight in the clinical picture and better management strategies [J].
Levi, M ;
de Jonge, E ;
van der Poll, T ;
ten Cate, H .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2001, 27 (06) :569-575